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Hematological Oncology. 2017;1–6.Abstract
Despite a general favourable outcome in limited stage diffuse large B‐cell lymphoma (DLBCL),
relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients
at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar
to the outcome after relapse in advanced stages. From January 2004 through December 2012, all
newly diagnosed patients with stage I(E) DLBCL were retrospectively analysed from 2 clinical
databases to investigate the relapse pattern and outcome in relation to initial treatment and
clinical characteristics. In 126 patients (median age 64 years), histologically confirmed stage I(E)
DLBCL was diagnosed. With a median follow‐up of 53 months (range 5‐132 months), 1
progressive disease and 18 relapses occurred. The 5‐year time to tumour progression and
disease‐specific survival were 85% (95% CI 79‐91%) and 92% (95% CI 87%‐97%), respectively.
We observed no significant difference in relapse localization, time to tumour progression, and
disease‐specific survival between patients treated with abbreviated R‐CHOP plus involved field
radiotherapy or with 6 to 8 cycles of R‐CHOP. Analysis of relapses showed relapse >5 years after
initial treatment (late relapse) in 5 of 19 patients (26%). Six of 19 patients (32%) had central
nervous system relapse. Three of 11 relapsed cases available for analysis (28%) showed an
MYC translocation, suggesting an overrepresentation in the relapse group. Outcome of patients
with a relapse was poor with a median survival after relapse of 8 months. Only 1 patient (5%)
underwent successful autologous stem cell transplantation. To improve outcome in these
patients, early identification of new biological factors such as a MYC translocation or a high risk
for CNS dissemination might be helpful. Moreover, treatment of any relapse after stage I disease
should be taken seriously. Salvage treatment should be similar to relapses after advanced DLBCL.
KEYWORDS
CNS, diffuse large B‐cell lymphoma, limited stage, MYC, relapse, survival1 | INTRODUCTION
Diffuse large B‐cell lymphoma (DLBCL) accounts for 25 to 30% of
adult non‐Hodgkin lymphomas.1 Twenty‐five to 40% of patients pres-
ent with limited stage disease, defined as stages I and II according to
the Ann Arbor classification.
Until the beginning of this century, optimal treatment for limited
stage DLBCL used to consist of 3 cycles of cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (CHOP) chemotherapy plus involved- - - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution Li
lished by John Wiley & Sons Ltdfield radiotherapy (IFRT). This combined modality approach resulted in
a significantly better overall survival (OS) than treatment with 8 cycles
of CHOP alone.2 The addition of rituximab to CHOP has increased OS
with 10‐15% in both limited stage and advanced stage DLBCL.3-5
Apparently, this became for many haematologists a reason to refrain
from consolidation IFRT for patients with stage I and II.6 Although
randomized controlled trials are lacking, a very large registry study
covering >59,000 patients strongly suggested that combined modality
therapy was associated with better OS, even in the rituximab era.6- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
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2 NIJLAND ET AL.Despite the generally favourable outcome, relapses still occur in
10 to 20% of patients with limited stage DLBCL and 5‐year OS ranges
between 75% and 94%, which suggests that salvage of relapses is
frequently unsuccessful.6-10 Clinical prognostic models only partially
identify patients at risk for relapse.2,11 Biological tumour characteris-
tics such as cell of origin and especially presence of MYC translocation
have prognostic significance in DLBCL.12,13
We decided to analyse in an observational cohort study the
relapses of patients with stage I(E) DLBCL focusing on (1) initial
therapy (only R‐CHOP vs. combined modality treatment), (2) clinical
characteristics and risk profile of the patient, (3) patterns of relapse,
(4) if available the presence of MYC breaks, and (5) the final outcome
after treatment. To this end, we used 2 large databases in the northern
part of the Netherlands, thereby avoiding trial‐based selection and
better approaching real life observations.2 | MATERIAL AND METHODS
2.1 | Study design and patient identification
Clinical data on all consecutive patients with histologically confirmed
stage I(E) DLBCL diagnosed during an 8‐year period from
January 1, 2004 through December 31, 2012 were retrieved from 2
clinical databases from 5 medical centres and 1 academic medical
centre. The combined databases are representative of the incidence,
characteristics, and treatments of patients in the northern part of the
Netherlands. Patients should have received at least 1 cycle of R‐CHOP.
Primary coetaneous, central nervous system (CNS) large B‐cell lym-
phoma, primary mediastinal B‐cell lymphoma, and immunodeficiency
lymphomas were excluded. At diagnosis, patients were staged by
fludeoxyglucose positron emission tomography (18FDG PET) and/or
computed tomography (CT) scans. The stage‐adjusted IPI and CNS
IPI were used to stratify patients.2,14 Pathological review was
performed by experienced haematopathologists (RK and AD).
Approval for this observational study was obtained from the Medical
Ethics Review Committee from Medical Centre Leeuwarden. Informed
consent was waived in accordance with Dutch regulations.2.2 | Treatment and follow‐up
Patients were categorized into 2 treatment regimens: combined modal-
ity treatment consisting of abbreviated R‐CHOP (3‐4 cycles) plus IFRT
or R‐CHOP only (6‐8 cycles). The number of R‐CHOP cycles adminis-
tered was registered for all patients. Staging was performed by 18FDG
PET/CT scan in 59% of patients (n = 74) and by CT scan in 41%
(n = 52). End of treatment response was assessed by 18FDG PET/CT
scan in 75% of patients (n = 91) and by CT scan in 25% (n = 31). Tumour
responses were classified as complete remission, partial response, stable
disease, or progressive disease (PD) according to the International
Working Group.15 In all patients, relapse was confirmed with 18FDG
PET scan, CT scan, and/or magnetic resonance imaging. Histological
confirmation of relapse (or in case of CNS localization multicolor flow
cytometry of spinal fluid) was available in 68% (n = 13) of patients. Rea-
sons for not performing histological conformation were early relapse
(n = 4) and CNS localization (n = 2). In case of PD or relapse, thesubsequent salvage treatment and response was retrieved from the clin-
ical records. Early treatment‐related mortality was restricted to death dur-
ing or ≤3 months after treatment. Relapses after 5 years were designated
as late relapses.16,17 Follow‐up was completed until December 2015.
2.3 | MYC fluorescence in situ hybridization analysis
For evaluation of a MYC translocation, formalin‐fixed paraffin‐
embedded tissue blocks were collected of the relapsed DLBCL cases.
Interphase fluorescence in situ hybridization (FISH) was performed on
3‐μm‐thick whole tissue sections of the primary tumour as previously
described by using Vysis break apart probes (Abbot Technologies).18
2.4 | Statistical analysis
Duration of follow‐up was calculated for all patients alive. The primary
endpoints were OS, disease‐specific survival (DSS), time to tumour pro-
gression (TTP), and survival after relapse. Overall survivalwas defined as
time from diagnosis until death (from any cause), DSS as the time from
diagnosis until death as a consequence of DLBCL, TTP as the time from
diagnosis until relapse or progression, and survival after relapse as the
time from relapse until death (from any cause).15 Survival curves were
estimated according to the Kaplan‐Meier method. Between‐group
differences in DSS and TTP were evaluated by using the log‐rank test.
All categorical variables were expressed as counts and percentages.
Where applicable, differences between groups were evaluated by
chi‐square for binary variables and independent t tests for continuous
variables. Cox regression was used for univariate analysis. Given the
low incidence of events no multivariate analysis was performed. A
2‐tailed P value of less than.05 indicated statistical significance. All anal-
yses were performed by using IBM SPSS Statistics version 22.3 | RESULTS
3.1 | Clinical characteristics
A total of 126 patients with a median age of 64 years were eligible for
analysis. At presentation, 41% (n = 50) of patients had a nodal localiza-
tion; extranodal sites consisted of gastrointestinal (20%, n = 25), bone
(10%, n = 13), and nasopharyngeal localization (11%, n = 14). Other sites
encompassed the remaining 18%, i.e., testis (n = 7), thyroid (n = 5),
breast (n = 5), and salivary glands (n = 2) (Figure SS1). High stage‐
adjusted IPI was observed in 19% (n = 23) of patients. Central nervous
system‐IPI 0‐1 (low risk), 2 to 3 (intermediate risk), and >3 (high risk)
were observed in 52% (n = 66), 47% (n = 59), and 1% (n = 1), respectively.
3.2 | Treatment
Of the 126 patients 97% (n = 122) completed, at least 3 cycles of
R‐CHOP were evaluable for comparison between treatment arms,
e.g., combined modality (68%, n = 83) or R‐CHOP alone (32%,
n = 39); see Figure 1 and Table 1. In patients receiving R‐CHOP, the
number of cycles was reduced in 8% of patients (n = 3) because of
previous tumour resection and treatment‐related toxicity. The cumula-
tive dosage of IFRT was 30 to 40 Gray. All patients with testicular
localization received CNS prophylaxis with intrathecal methotrexate.
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FIGURE 1 Schematic representation of the 126 patients with a stage
I(E) diffuse large B‐cell lymphoma according to treatment regimen. One
hundred twenty‐two patients completed therapy. Four patients died
before completing 3 cycles of (R)CHOP. TRM, treatment‐related
mortality; PD, progressive disease
TABLE 1 Clinical characteristics of 122 patients with stage I(E) diffuse







IFRT (n = 83) P value
Gender .04
Male (%) 68 (56) 27 (69) 41 (49)
Female (%) 54 (44) 12 (31) 42 (51)
Median age (range) 64 (15‐87) 63 (15‐83) 66 (28‐87) .43
Age < 60 (%) 48 (39) 16 (41) 32 (39) .79
Age > 60 (%) 74 (61) 23 (59) 51 (61)
Localization <.01
Nodal (%) 50 (41) 8 (21) 42 (51)
Extranodal (%) 72 (59) 31 (79) 41 (49)
Performance .37
WHO < 2 (%) 118 (97) 39 (100) 79 (95)
WHO ≥ 2 (%) 4 (3) 0 (0) 4 (5)
LDH .01
Normal (%) 99 (81) 26 (67) 73 (88)
Elevated (%) 23 (19) 13 (33) 10 (12)
Stage‐adjusted IPI .19
0‐1 (%) 99 (81) 29 (74) 70 (84)
2‐3 (%) 23 (19) 10 (26) 13 (16)
NIJLAND ET AL. 3Patients with extranodal disease and those with elevated LDH more
frequently received R‐CHOP only (P < .01 and P = .01, Table 1).3.3 | Clinical and biological characteristics of relapse
One patient had PDduring the first 3 cycles of R‐CHOP, and 18 patients
experienced a relapse. Of these 18 patients, 28% of patients (n = 5) hada relapsemore than 5 years after diagnosis: 3 of 14 patients treatedwith
abbreviated R‐CHOP plus IFRT and 2 of 4 patients treated with
R‐CHOP (p 0.52) (Figure 1). In 79% of cases (n = 15), the relapse/pro-
gression occurred at a site distant from the initial tumour localization.
In 32% of cases (n = 6), this involved the CNS, with either meningeal
and/or parenchymal localization. Two of the CNS relapses occurred in
patients with a testicular lymphoma, despite CNS prophylaxis. In the
remaining cases, the primary tumour had nodal (n = 2) and nasopharyn-
geal localizations (n = 2) (Figure 2). The initial calculatedCNS‐IPI was low
(n = 3) and intermediate (n = 3). In addition, 1 patient with initial nodal
localization had a testicular relapse, another sanctuary site.
Of the 19 relapsed/progressive DLBCL, 58% of cases (n = 11) had
tissue blocks with sufficient tumour material for MYC‐FISH analysis. In
28% of cases (n = 3), an MYC translocation could be demonstrated. All
these MYC positive DLBCL were observed in patients with an early
relapse. None of the evaluable CNS relapses had a MYC translocation
(Figure 2).3.4 | Patient outcome
The median duration of follow‐up of the 126 patients was 53 months
(range 5‐132). Twenty‐seven patients died (11 of relapse; 16 unrelated).
The 5‐year TTP, DSS, and OS for the entire cohort were 85% (95% CI
79‐91%), 92% (95% CI 87%‐97%), and 80% (95% CI 73‐86%),
respectively (Figure 3A and B). In univariate analysis of 122 patients
completing therapy, age had the strongest association with shorter TTP
(Table 2). Age > 60 years and elevated LDH, both composites of stage
adjusted IPI, were associated with a shorter DSS (Table 2). Localization
and treatment regimen were not found to be prognostic factors
(Figure S2A). Univariate analysis showed that age > 60 years (HR 9.1,
95% CI 2.1‐38, P < .01), but not localization, LDH, or treatment regimen
was associated with a shorter OS (Figure S2B).3.5 | Treatment after relapse
The median age of relapsing patients was 77 years (range 41‐83). The
median survival after relapse was 8 months (Figure 3C). Treatment of
patients who relapsed consisted of rituximab, dexamethasone,
cytarabine, and cisplatin salvage chemotherapy (16%, n = 3),
retreatment with R‐CHOP (10%, n = 2), palliative chemotherapy (16%,
n = 3), radiotherapy (32%, n = 6), and palliative care (26%, n = 5). Only
1 patient (5%) underwent high dose chemotherapy followed by
autologous stem cell transplantation as part of the salvage regimen. A
second remission was achieved in 3 of 5 (60%) patients receiving
curative chemotherapy, in 1 patient (33%) treated with “intended”
palliative chemotherapy, and in 2 patients (33%) treated with radiother-
apy. One‐year survival after relapse for patients receiving salvage
radiotherapy or chemotherapy was 53% (95% CI 27‐79%).4 | DISCUSSION
In this population‐based cohort study with a long median follow‐up,
we followed all consecutive patients with newly diagnosed DLBCL
stage I(E) during an 8‐year period. We observed no differences in
relapse localization, TTP, and DSS between patients treated with







Progression 3-4 R-CHOP plus IFRT 6-8 R-CHOP
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< 5 years > 5 years
Initial site Distant site CNS
No MYC breakage MYC breakage Not evaluable
FIGURE 2 Schematic overview of clinical and biological characteristics
of the 19 patients with a stage I(E) diffuse large B‐cell lymphoma who
progressed during or relapsed after treatment. Patients are categorized
according to the type of treatment received [Colour figure can be
viewed at wileyonlinelibrary.com]
4 NIJLAND ET AL.abbreviated R‐CHOP plus IFRT and R‐CHOP only. Obviously, this was
not a randomized comparison but a reflection of real‐life approaches.
Patients with extranodal disease more frequently received R‐CHOP,
reflecting physicians' choice to avoid radiotherapy‐induced toxicity.(A)
(C)
(B
FIGURE 3 A, Kaplan Meier curves for overall survival (OS) and disease‐spe
cell lymphoma (DLBCL). The 5‐year OS and DSS are 80 ± 6 and 92 ± 5%, re
the 126 patients with a stage I (E) DLBCL. At 5 years, the TTF was 85 ± 6%
relapsed stage I(E) DLBCL. Median OS is 8.0 monthsBy looking into the characteristics of relapsed patients, we made
several observations that offer a reason for the occurrence of relapses
in these good risk patients.
Regardless of initial therapy, one‐third of relapses (26%) occurred
more than 5 years after therapy. Although late relapses have been
observed in the pre‐rituximab era,17 we and others observed these late
relapses in patients with limited stage DLBCL treated with rituximab as
well.16 Although clonal relationship in late relapses is established, the
biology underlying the long interval remains unclear.19
Most relapses (73%, n = 15) arose at distant sites, indicative of
good local tumour control with either abbreviated R‐CHOP plus radio-
therapy or R‐CHOP. In nearly one‐third of relapses, there was CNS
involvement. Because rituximab and CHOP have only limited activity
in the CNS, it is unlikely that either of the treatment regimens will
prevent the CNS relapses.20 Even when initial CNS prophylaxis with
intrathecal MTX is provided, CNS relapses can occur as illustrated by
2 patients with lymphoma of the testes in our study.21 Recently, the
CNS‐IPI as risk model for CNS relapse in patients with DLBCL was
established to identify patients at highest risk for CNS relapse.14 In
patients with a low‐risk CNS‐IPI, less than 1% showed a CNS relapse.)
cific survival (DSS) of the 126 patients with a stage I(E) diffuse large B‐
spectively. B, Kaplan Meier curve for time to treatment failure (TTF) of
. C, Kaplan Meier curve for survival after relapse of 19 patients with a
TABLE 2 Univariate analysis of factors in time to tumour progression (TTP) and disease specific survival (DSS) of 122 stage I(E) diffuse large B‐cell
lymphoma patients who completed therapy
% Hazard Ratio TTP 95% CI P value Hazard Ratio DSS 95% CI P value
Gender
Male 56 Reference Reference
Female 44 0.97 0.4‐2.5 0.94 0.94 0.3‐3.1 0.92
Age
<60 years 39 Reference Reference
>60 years 61 4.1 1.2‐14 0.03 3.6 0.8‐17 0.06
Localization
Nodal 41 Reference Reference
Extranodal 59 1.2 0.5‐3.0 0.72 1.2 0.3‐4.4 0.80
LDH
Normal 81 Reference Reference
Elevated 19 2.0 0.7‐5.8 0.19 4.4 1.3‐15 0.02
Stage‐adjusted IPI
0‐1 81 Reference Reference
2‐3 19 2.7 1.0‐7.5 0.05 4.5 1.3‐15 0.02
Treatment regimen
Abb R‐CHOP + IFRT 68 Reference Reference
R‐CHOP 32 0.66 0.2‐2.0 0.47 2.0 0.6‐6.9 0.28
NIJLAND ET AL. 5However, as shown in our study, with stage I(E) DLBCL, 5% of 126
patients with initial low‐risk CNS‐IPI had a CNS relapse.
It was recently reported that in contrast to advanced stage DLBCL,
the cell‐of‐origin is not prognostic in limited stage disease.9,13 To
impact prognosis of these good risk patients, a biomarker, such as
MYC breaks, might be helpful.12 We found an MYC translocation in 3
of 11 evaluable relapsed cases. It is plausible that in the relapsed
setting, 15 to 20% of DLBCL harbour an MYC translocation.22
Although the number of analysed patients is low, we found no MYC
positive DLBCL in late relapses. Despite an increased risk of CNS
dissemination in MYC positive DLBCL, no translocation was detected
in the 2 evaluable CNS relapses.23
Combined analysis showed that two‐third of relapses could be
assigned to either a late relapse, CNS relapse, or MYC positive DLBCL.
In general, outcome of patients with relapsed or refractory DLBCL is
very poor, with the exception of more favourable outcome in relapses
more than 1 year after treatment.24 We observed a similar poor out-
come in patients with relapsed stage I(E) DLBCL. This can partially be
explained by the old age of the relapsed patients, limiting therapeutic
options. Because the median age of patients with a DLBCL in the gen-
eral population is 68 years, this is an observation in line with general
practice. Furthermore, treatment options for relapsed DLBCL in the
CNS are limited and patients with an MYC translocation tend to have
a poor response to salvage chemotherapy.25,26 Salvage therapy for a
relapse after stage I(E) disease is not trivial and emphasizes the neces-
sity to improve first line treatment in these patients as well.5 | CONCLUSIONS
Despite a general favourable outcome in stage I(E) DLBCL, 15% of
patients relapsed despite previous R‐CHOP therapy and survival afterrelapse was short. Analysis of relapses showed that more than half of
cases could be assigned to either a late relapse or CNS relapse.
Interestingly, there is a suggestion that MYC positive DLBCL was
overrepresented in the relapse group. Although numbers are small,
our results emphasize the necessity to improve first line treatment in
these patients as well. Any relapse after stage I disease should be taken
seriously, and patients need similar intensive salvage therapy as after
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